

FIRST REGULAR SESSION

HOUSE BILL NO. 620

96TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVES HOLSMAN (Sponsor), ATKINS,
TALBOY AND WALTON GRAY (Co-sponsors).

1338L.011

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal sections 195.010, 195.017, and 195.202, RSMo, and to enact in lieu thereof four new sections relating to industrial hemp, with existing penalty provisions.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Sections 195.010, 195.017, and 195.202, RSMo, are repealed and four new
2 sections enacted in lieu thereof, to be known as sections 195.010, 195.017, 195.202, and
3 195.203, to read as follows:

195.010. The following words and phrases as used in sections 195.005 to 195.425,
2 unless the context otherwise requires, mean:

3 (1) "Addict", a person who habitually uses one or more controlled substances to such an
4 extent as to create a tolerance for such drugs, and who does not have a medical need for such
5 drugs, or who is so far addicted to the use of such drugs as to have lost the power of self-control
6 with reference to his addiction;

7 (2) "Administer", to apply a controlled substance, whether by injection, inhalation,
8 ingestion, or any other means, directly to the body of a patient or research subject by:

9 (a) A practitioner (or, in his presence, by his authorized agent); or

10 (b) The patient or research subject at the direction and in the presence of the practitioner;

11 (3) "Agent", an authorized person who acts on behalf of or at the direction of a
12 manufacturer, distributor, or dispenser. The term does not include a common or contract carrier,
13 public warehouseman, or employee of the carrier or warehouseman while acting in the usual and
14 lawful course of the carrier's or warehouseman's business;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

15 (4) "Attorney for the state", any prosecuting attorney, circuit attorney, or attorney general
16 authorized to investigate, commence and prosecute an action under sections 195.005 to 195.425;

17 (5) "Controlled substance", a drug, substance, or immediate precursor in Schedules I
18 through V listed in sections 195.005 to 195.425;

19 (6) "Controlled substance analogue", a substance the chemical structure of which is
20 substantially similar to the chemical structure of a controlled substance in Schedule I or II and:

21 (a) Which has a stimulant, depressant, or hallucinogenic effect on the central nervous
22 system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
23 nervous system of a controlled substance included in Schedule I or II; or

24 (b) With respect to a particular individual, which that individual represents or intends
25 to have a stimulant, depressant, or hallucinogenic effect on the central nervous system
26 substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous
27 system of a controlled substance included in Schedule I or II. The term does not include a
28 controlled substance; any substance for which there is an approved new drug application; any
29 substance for which an exemption is in effect for investigational use, for a particular person,
30 under Section 505 of the federal Food, Drug and Cosmetic Act (21 U.S.C. 355) to the extent
31 conduct with respect to the substance is pursuant to the exemption; or any substance to the extent
32 not intended for human consumption before such an exemption takes effect with respect to the
33 substance;

34 (7) "Counterfeit substance", a controlled substance which, or the container or labeling
35 of which, without authorization, bears the trademark, trade name, or other identifying mark,
36 imprint, number or device, or any likeness thereof, of a manufacturer, distributor, or dispenser
37 other than the person who in fact manufactured, distributed, or dispensed the substance;

38 (8) "Deliver" or "delivery", the actual, constructive, or attempted transfer from one
39 person to another of drug paraphernalia or of a controlled substance, or an imitation controlled
40 substance, whether or not there is an agency relationship, and includes a sale;

41 (9) "Dentist", a person authorized by law to practice dentistry in this state;

42 (10) "Depressant or stimulant substance":

43 (a) A drug containing any quantity of barbituric acid or any of the salts of barbituric acid
44 or any derivative of barbituric acid which has been designated by the United States Secretary of
45 Health and Human Services as habit forming under 21 U.S.C. 352(d);

46 (b) A drug containing any quantity of:

47 a. Amphetamine or any of its isomers;

48 b. Any salt of amphetamine or any salt of an isomer of amphetamine; or

49 c. Any substance the United States Attorney General, after investigation, has found to
50 be, and by regulation designated as, habit forming because of its stimulant effect on the central
51 nervous system;

52 (c) Lysergic acid diethylamide; or

53 (d) Any drug containing any quantity of a substance that the United States Attorney
54 General, after investigation, has found to have, and by regulation designated as having, a
55 potential for abuse because of its depressant or stimulant effect on the central nervous system or
56 its hallucinogenic effect;

57 (11) "Dispense", to deliver a narcotic or controlled dangerous drug to an ultimate user
58 or research subject by or pursuant to the lawful order of a practitioner including the prescribing,
59 administering, packaging, labeling, or compounding necessary to prepare the substance for such
60 delivery. "Dispenser" means a practitioner who dispenses;

61 (12) "Distribute", to deliver other than by administering or dispensing a controlled
62 substance;

63 (13) "Distributor", a person who distributes;

64 (14) "Drug":

65 (a) Substances recognized as drugs in the official United States Pharmacopoeia, Official
66 Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
67 supplement to any of them;

68 (b) Substances intended for use in the diagnosis, cure, mitigation, treatment or
69 prevention of disease in humans or animals;

70 (c) Substances, other than food, intended to affect the structure or any function of the
71 body of humans or animals; and

72 (d) Substances intended for use as a component of any article specified in this
73 subdivision. It does not include devices or their components, parts or accessories;

74 (15) "Drug-dependent person", a person who is using a controlled substance and who
75 is in a state of psychic or physical dependence, or both, arising from the use of such substance
76 on a continuous basis. Drug dependence is characterized by behavioral and other responses
77 which include a strong compulsion to take the substance on a continuous basis in order to
78 experience its psychic effects or to avoid the discomfort caused by its absence;

79 (16) "Drug enforcement agency", the Drug Enforcement Administration in the United
80 States Department of Justice, or its successor agency;

81 (17) "Drug paraphernalia", all equipment, products, substances and materials of any kind
82 which are used, intended for use, or designed for use, in planting, propagating, cultivating,
83 growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing,
84 storing, containing, concealing, injecting, ingesting, inhaling, or otherwise introducing into the

85 human body a controlled substance or an imitation controlled substance in violation of sections
86 195.005 to 195.425. It includes, but is not limited to:

87 (a) Kits used, intended for use, or designed for use in planting, propagating, cultivating,
88 growing or harvesting of any species of plant which is a controlled substance or from which a
89 controlled substance can be derived;

90 (b) Kits used, intended for use, or designed for use in manufacturing, compounding,
91 converting, producing, processing, or preparing controlled substances or imitation controlled
92 substances;

93 (c) Isomerization devices used, intended for use, or designed for use in increasing the
94 potency of any species of plant which is a controlled substance or an imitation controlled
95 substance;

96 (d) Testing equipment used, intended for use, or designed for use in identifying, or in
97 analyzing the strength, effectiveness or purity of controlled substances or imitation controlled
98 substances;

99 (e) Scales and balances used, intended for use, or designed for use in weighing or
100 measuring controlled substances or imitation controlled substances;

101 (f) Dilutents and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose
102 and lactose, used, intended for use, or designed for use in cutting controlled substances or
103 imitation controlled substances;

104 (g) Separation gins and sifters used, intended for use, or designed for use in removing
105 twigs and seeds from, or in otherwise cleaning or refining, marijuana;

106 (h) Blenders, bowls, containers, spoons and mixing devices used, intended for use, or
107 designed for use in compounding controlled substances or imitation controlled substances;

108 (I) Capsules, balloons, envelopes and other containers used, intended for use, or designed
109 for use in packaging small quantities of controlled substances or imitation controlled substances;

110 (j) Containers and other objects used, intended for use, or designed for use in storing or
111 concealing controlled substances or imitation controlled substances;

112 (k) Hypodermic syringes, needles and other objects used, intended for use, or designed
113 for use in parenterally injecting controlled substances or imitation controlled substances into the
114 human body;

115 (l) Objects used, intended for use, or designed for use in ingesting, inhaling, or otherwise
116 introducing marijuana, cocaine, hashish, or hashish oil into the human body, such as:

117 a. Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without screens,
118 permanent screens, hashish heads, or punctured metal bowls;

119 b. Water pipes;

120 c. Carburetion tubes and devices;

- 121 d. Smoking and carburetion masks;
- 122 e. Roach clips meaning objects used to hold burning material, such as a marijuana
123 cigarette, that has become too small or too short to be held in the hand;
- 124 f. Miniature cocaine spoons and cocaine vials;
- 125 g. Chamber pipes;
- 126 h. Carburetor pipes;
- 127 I. Electric pipes;
- 128 j. Air-driven pipes;
- 129 k. Chillums;
- 130 l. Bongs;
- 131 m. Ice pipes or chillers;
- 132 (m) Substances used, intended for use, or designed for use in the manufacture of a
133 controlled substance; In determining whether an object, product, substance or material is drug
134 paraphernalia, a court or other authority should consider, in addition to all other logically
135 relevant factors, the following:
- 136 (a) Statements by an owner or by anyone in control of the object concerning its use;
- 137 (b) Prior convictions, if any, of an owner, or of anyone in control of the object, under any
138 state or federal law relating to any controlled substance or imitation controlled substance;
- 139 (c) The proximity of the object, in time and space, to a direct violation of sections
140 195.005 to 195.425;
- 141 (d) The proximity of the object to controlled substances or imitation controlled
142 substances;
- 143 (e) The existence of any residue of controlled substances or imitation controlled
144 substances on the object;
- 145 (f) Direct or circumstantial evidence of the intent of an owner, or of anyone in control
146 of the object, to deliver it to persons who he knows, or should reasonably know, intend to use
147 the object to facilitate a violation of sections 195.005 to 195.425; the innocence of an owner, or
148 of anyone in control of the object, as to direct violation of sections 195.005 to 195.425 shall not
149 prevent a finding that the object is intended for use, or designed for use as drug paraphernalia;
- 150 (g) Instructions, oral or written, provided with the object concerning its use;
- 151 (h) Descriptive materials accompanying the object which explain or depict its use;
- 152 (I) National or local advertising concerning its use;
- 153 (j) The manner in which the object is displayed for sale;
- 154 (k) Whether the owner, or anyone in control of the object, is a legitimate supplier of like
155 or related items to the community, such as a licensed distributor or dealer of tobacco products;

- 156 (l) Direct or circumstantial evidence of the ratio of sales of the object to the total sales
157 of the business enterprise;
- 158 (m) The existence and scope of legitimate uses for the object in the community;
- 159 (n) Expert testimony concerning its use;
- 160 (o) The quantity, form or packaging of the product, substance or material in relation to
161 the quantity, form or packaging associated with any legitimate use for the product, substance or
162 material;
- 163 (18) "Federal narcotic laws", the laws of the United States relating to controlled
164 substances;
- 165 (19) "Hospital", a place devoted primarily to the maintenance and operation of facilities
166 for the diagnosis, treatment or care, for not less than twenty-four hours in any week, of three or
167 more nonrelated individuals suffering from illness, disease, injury, deformity or other abnormal
168 physical conditions; or a place devoted primarily to provide, for not less than twenty-four
169 consecutive hours in any week, medical or nursing care for three or more nonrelated individuals.
170 The term "hospital" does not include convalescent, nursing, shelter or boarding homes as defined
171 in chapter 198;
- 172 (20) "Immediate precursor", a substance which:
- 173 (a) The state department of health and senior services has found to be and by rule
174 designates as being the principal compound commonly used or produced primarily for use in the
175 manufacture of a controlled substance;
- 176 (b) Is an immediate chemical intermediary used or likely to be used in the manufacture
177 of a controlled substance; and
- 178 (c) The control of which is necessary to prevent, curtail or limit the manufacture of the
179 controlled substance;
- 180 (21) "Imitation controlled substance", a substance that is not a controlled substance,
181 which by dosage unit appearance (including color, shape, size and markings), or by
182 representations made, would lead a reasonable person to believe that the substance is a controlled
183 substance. In determining whether the substance is an "imitation controlled substance" the court
184 or authority concerned should consider, in addition to all other logically relevant factors, the
185 following:
- 186 (a) Whether the substance was approved by the federal Food and Drug Administration
187 for over-the-counter (nonprescription or nonlegend) sales and was sold in the federal Food and
188 Drug Administration approved package, with the federal Food and Drug Administration
189 approved labeling information;
- 190 (b) Statements made by an owner or by anyone else in control of the substance
191 concerning the nature of the substance, or its use or effect;

192 (c) Whether the substance is packaged in a manner normally used for illicit controlled
193 substances;

194 (d) Prior convictions, if any, of an owner, or anyone in control of the object, under state
195 or federal law related to controlled substances or fraud;

196 (e) The proximity of the substances to controlled substances;

197 (f) Whether the consideration tendered in exchange for the noncontrolled substance
198 substantially exceeds the reasonable value of the substance considering the actual chemical
199 composition of the substance and, where applicable, the price at which over-the-counter
200 substances of like chemical composition sell. An imitation controlled substance does not include
201 a placebo or registered investigational drug either of which was manufactured, distributed,
202 possessed or delivered in the ordinary course of professional practice or research;

203 (22) "**Industrial hemp**", **cannabis sativa L. containing no greater than one percent**
204 **tetrahydrocannabinols (THC)**;

205 (23) "Laboratory", a laboratory approved by the department of health and senior services
206 as proper to be entrusted with the custody of controlled substances but does not include a
207 pharmacist who compounds controlled substances to be sold or dispensed on prescriptions;

208 [(23)] (24) "Manufacture", the production, preparation, propagation, compounding or
209 processing of drug paraphernalia or of a controlled substance, or an imitation controlled
210 substance, either directly or by extraction from substances of natural origin, or independently by
211 means of chemical synthesis, or by a combination of extraction and chemical synthesis, and
212 includes any packaging or repackaging of the substance or labeling or relabeling of its container.
213 This term does not include the preparation or compounding of a controlled substance or an
214 imitation controlled substance or the preparation, compounding, packaging or labeling of a
215 narcotic or dangerous drug:

216 (a) By a practitioner as an incident to his administering or dispensing of a controlled
217 substance or an imitation controlled substance in the course of his professional practice, or

218 (b) By a practitioner or his authorized agent under his supervision, for the purpose of,
219 or as an incident to, research, teaching or chemical analysis and not for sale;

220 [(24)] (25) "Marijuana", all parts of the plant genus Cannabis in any species or form
221 thereof, including, but not limited to Cannabis Sativa L., **except industrial hemp as defined in**
222 **this section**, Cannabis Indica, Cannabis Americana, Cannabis Ruderalis, and Cannabis Gigantea,
223 whether growing or not, the seeds thereof, the resin extracted from any part of the plant; and
224 every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or
225 resin. It does not include the mature stalks of the plant, fiber produced from the stalks, oil or
226 cake made from the seeds of the plant, any other compound, manufacture, salt, derivative,

227 mixture or preparation of the mature stalks (except the resin extracted therefrom), fiber, oil or
228 cake, or the sterilized seed of the plant which is incapable of germination;

229 [(25)] **(26)** "Methamphetamine precursor drug", any drug containing ephedrine,
230 pseudoephedrine, phenylpropanolamine, or any of their salts, optical isomers, or salts of optical
231 isomers;

232 [(26)] **(27)** "Narcotic drug", any of the following, whether produced directly or indirectly
233 by extraction from substances of vegetable origin, or independently by means of chemical
234 synthesis, or by a combination of extraction and chemical analysis:

235 (a) Opium, opiate, and any derivative, of opium or opiate, including their isomers, esters,
236 ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers,
237 esters, ethers, and salts is possible within the specific chemical designation. The term does not
238 include the isoquinoline alkaloids of opium;

239 (b) Coca leaves, but not including extracts of coca leaves from which cocaine, ecgonine,
240 and derivatives of ecgonine or their salts have been removed;

241 (c) Cocaine or any salt, isomer, or salt of isomer thereof;

242 (d) Ecgonine, or any derivative, salt, isomer, or salt of isomer thereof;

243 (e) Any compound, mixture, or preparation containing any quantity of any substance
244 referred to in paragraphs (a) to (d) of this subdivision;

245 [(27)] **(28)** "Official written order", an order written on a form provided for that purpose
246 by the United States Commissioner of Narcotics, under any laws of the United States making
247 provision therefor, if such order forms are authorized and required by federal law, and if no such
248 order form is provided, then on an official form provided for that purpose by the department of
249 health and senior services;

250 [(28)] **(29)** "Opiate", any substance having an addiction-forming or addiction-sustaining
251 liability similar to morphine or being capable of conversion into a drug having addiction-forming
252 or addiction-sustaining liability. The term includes its racemic and levorotatory forms. It does
253 not include, unless specifically controlled under section 195.017, the dextrorotatory isomer of
254 3-methoxy-n-methyl-morphinan and its salts (dextromethorphan);

255 [(29)] **(30)** "Opium poppy", the plant of the species *Papaver somniferum* L., except its
256 seeds;

257 [(30)] **(31)** "Over-the-counter sale", a retail sale licensed pursuant to chapter 144 of a
258 drug other than a controlled substance;

259 [(31)] **(32)** "Person", an individual, corporation, government or governmental
260 subdivision or agency, business trust, estate, trust, partnership, joint venture, association, or any
261 other legal or commercial entity;

262 [(32)] (33) "Pharmacist", a licensed pharmacist as defined by the laws of this state, and
263 where the context so requires, the owner of a store or other place of business where controlled
264 substances are compounded or dispensed by a licensed pharmacist; but nothing in sections
265 195.005 to 195.425 shall be construed as conferring on a person who is not registered nor
266 licensed as a pharmacist any authority, right or privilege that is not granted to him by the
267 pharmacy laws of this state;

268 [(33)] (34) "Poppy straw", all parts, except the seeds, of the opium poppy, after mowing;

269 [(34)] (35) "Possessed" or "possessing a controlled substance", a person, with the
270 knowledge of the presence and nature of a substance, has actual or constructive possession of
271 the substance. A person has actual possession if he has the substance on his person or within
272 easy reach and convenient control. A person who, although not in actual possession, has the
273 power and the intention at a given time to exercise dominion or control over the substance either
274 directly or through another person or persons is in constructive possession of it. Possession may
275 also be sole or joint. If one person alone has possession of a substance possession is sole. If two
276 or more persons share possession of a substance, possession is joint;

277 [(35)] (36) "Practitioner", a physician, dentist, optometrist, podiatrist, veterinarian,
278 scientific investigator, pharmacy, hospital or other person licensed, registered or otherwise
279 permitted by this state to distribute, dispense, conduct research with respect to or administer or
280 to use in teaching or chemical analysis, a controlled substance in the course of professional
281 practice or research in this state, or a pharmacy, hospital or other institution licensed, registered,
282 or otherwise permitted to distribute, dispense, conduct research with respect to or administer a
283 controlled substance in the course of professional practice or research;

284 [(36)] (37) "Production", includes the manufacture, planting, cultivation, growing, or
285 harvesting of drug paraphernalia or of a controlled substance or an imitation controlled
286 substance;

287 [(37)] (38) "Registry number", the number assigned to each person registered under the
288 federal controlled substances laws;

289 [(38)] (39) "Sale", includes barter, exchange, or gift, or offer therefor, and each such
290 transaction made by any person, whether as principal, proprietor, agent, servant or employee;

291 [(39)] (40) "State" when applied to a part of the United States, includes any state, district,
292 commonwealth, territory, insular possession thereof, and any area subject to the legal authority
293 of the United States of America;

294 [(40)] (41) "Ultimate user", a person who lawfully possesses a controlled substance or
295 an imitation controlled substance for his own use or for the use of a member of his household
296 or for administering to an animal owned by him or by a member of his household;

297 [(41)] (42) "Wholesaler", a person who supplies drug paraphernalia or controlled
298 substances or imitation controlled substances that he himself has not produced or prepared, on
299 official written orders, but not on prescriptions.

195.017. 1. The department of health and senior services shall place a substance in
2 Schedule I if it finds that the substance:

3 (1) Has high potential for abuse; and

4 (2) Has no accepted medical use in treatment in the United States or lacks accepted
5 safety for use in treatment under medical supervision.

6 2. Schedule I:

7 (1) The controlled substances listed in this subsection are included in Schedule I;

8 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
9 of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these
10 isomers, esters, ethers and salts is possible within the specific chemical designation:

11 (a) Acetyl-alpha-methylfentanyl;

12 (b) Acetylmethadol;

13 (c) Allylprodine;

14 (d) Alphacetylmethadol;

15 (e) Alphameprodine;

16 (f) Alphamethadol;

17 (g) Alpha-methylfentanyl;

18 (h) Alpha-methylthiofentanyl;

19 (I) Benzethidine;

20 (j) Betacetylmethadol;

21 (k) Beta-hydroxyfentanyl;

22 (l) Beta-hydroxy-3-methylfentanyl;

23 (m) Betameprodine;

24 (n) Betamethadol;

25 (o) Betaprodine;

26 (p) Clonitazene;

27 (q) Dextromoramide;

28 (r) Diampromide;

29 (s) Diethylthiambutene;

30 (t) Difenoxin;

31 (u) Dimenoxadol;

32 (v) Dimepheptanol;

33 (w) Dimethylthiambutene;

- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacilmorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;
- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;

- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (I) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphanol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myrophine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;
- 89 (u) Normorphine;
- 90 (v) Pholcodine;
- 91 (w) Thebacon;
- 92 (4) Any material, compound, mixture or preparation which contains any quantity of the
- 93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
- 94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
- 95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (I) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;

- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
- 110 isomers;
- 111 (o) Alpha-ethyltryptamine;
- 112 (p) Alpha-methyltryptamine;
- 113 (q) Bufotenine;
- 114 (r) D e x a n a b i n o l ,
- 115 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10
- 116 a-tetrahydrobenzo[c]chromen-1-ol;
- 117 (s) Diethyltryptamine;
- 118 (t) Dimethyltryptamine;
- 119 (u) 5-methoxy-N,N-diisopropyltryptamine;
- 120 (v) Ibogaine;
- 121 (w) Indole, or 1-butyl-3(1-naphthoyl)indole;
- 122 (x) Indole, or 1-pentyl-3(1-naphthoyl)indole;
- 123 (y) Lysergic acid diethylamide;
- 124 (z) Marijuana or marihuana, **except industrial hemp as defined in section 195.010**;
- 125 (aa) Mescaline;
- 126 (bb) Parahexyl;
- 127 (cc) Peyote, to include all parts of the plant presently classified botanically as
- 128 Lophophora Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any
- 129 part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of
- 130 the plant, its seed or extracts;
- 131 (d d) P h e n o l , C P 47, 497 & homologues, or
- 132 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol), where side chain n=5, and
- 133 homologues where side chain n=4,6, or 7;
- 134 (ee) N-ethyl-3-piperidyl benzilate;
- 135 (ff) N-methyl-3-piperidyl benzilate;
- 136 (gg) Psilocybin;
- 137 (hh) Psilocyn;
- 138 (ii) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis
- 139 plant), **except industrial hemp as defined in section 195.010**, as well as synthetic equivalents
- 140 of the substances contained in the cannabis plant, or in the resinous extractives of such plant, or

141 synthetic substances, derivatives, and their isomers with similar chemical structure and
142 pharmacological activity to those substances contained in the plant, such as the following:

- 143 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 144 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 145 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 146 d. Any compounds of these structures, regardless of numerical designation of atomic
147 positions covered;

148 (jj) Ethylamine analog of phencyclidine;

149 (kk) Pyrrolidine analog of phencyclidine;

150 (ll) Thiophene analog of phencyclidine;

151 (mm) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

152 (nn) *Salvia divinorum*;

153 (oo) Salvinorin A;

154 (5) Any material, compound, mixture or preparation containing any quantity of the
155 following substances having a depressant effect on the central nervous system, including their
156 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
157 isomers is possible within the specific chemical designation:

158 (a) Gamma-hydroxybutyric acid;

159 (b) Mecloqualone;

160 (c) Methaqualone;

161 (6) Any material, compound, mixture or preparation containing any quantity of the
162 following substances having a stimulant effect on the central nervous system, including their
163 salts, isomers and salts of isomers:

164 (a) Aminorex;

165 (b) N-benzylpiperazine;

166 (c) Cathinone;

167 (d) Fenethylamine;

168 (e) Methcathinone;

169 (f) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

170 (g) N-ethylamphetamine;

171 (h) N,N-dimethylamphetamine;

172 (7) A temporary listing of substances subject to emergency scheduling under federal law
173 shall include any material, compound, mixture or preparation which contains any quantity of the
174 following substances:

175 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
176 salts and salts of isomers;

177 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
178 optical isomers, salts and salts of isomers;

179 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
180 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
181 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

182 3. The department of health and senior services shall place a substance in Schedule II
183 if it finds that:

184 (1) The substance has high potential for abuse;

185 (2) The substance has currently accepted medical use in treatment in the United States,
186 or currently accepted medical use with severe restrictions; and

187 (3) The abuse of the substance may lead to severe psychic or physical dependence.

188 4. The controlled substances listed in this subsection are included in Schedule II:

189 (1) Any of the following substances whether produced directly or indirectly by extraction
190 from substances of vegetable origin, or independently by means of chemical synthesis, or by
191 combination of extraction and chemical synthesis:

192 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
193 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
194 nalmefene, naloxone and naltrexone, and their respective salts but including the following:

195 a. Raw opium;

196 b. Opium extracts;

197 c. Opium fluid;

198 d. Powdered opium;

199 e. Granulated opium;

200 f. Tincture of opium;

201 g. Codeine;

202 h. Ethylmorphine;

203 I. Etorphine hydrochloride;

204 j. Hydrocodone;

205 k. Hydromorphone;

206 l. Metopon;

207 m. Morphine;

208 n. Oxycodone;

209 o. Oxymorphone;

210 p. Thebaine;

- 211 (b) Any salt, compound, derivative, or preparation thereof which is chemically
212 equivalent or identical with any of the substances referred to in this subdivision, but not
213 including the isoquinoline alkaloids of opium;
- 214 (c) Opium poppy and poppy straw;
- 215 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
216 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
217 with any of these substances, but not including decocainized coca leaves or extractions which
218 do not contain cocaine or ecgonine;
- 219 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
220 or powder form which contains the phenanthrene alkaloids of the opium poppy);
- 221 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
222 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
223 the specific chemical designation, dextrorphan and levopropoxyphene excepted:
- 224 (a) Alfentanil;
- 225 (b) Alphaprodine;
- 226 (c) Anileridine;
- 227 (d) Bezitramide;
- 228 (e) Bulk dextropropoxyphene;
- 229 (f) Carfentanil;
- 230 (g) Dihydrocodeine;
- 231 (h) Diphenoxylate;
- 232 (I) Fentanyl;
- 233 (j) Isomethadone;
- 234 (k) Levo-alphacetylmethadol;
- 235 (l) Levomethorphan;
- 236 (m) Levorphanol;
- 237 (n) Metazocine;
- 238 (o) Methadone;
- 239 (p) Meperidine;
- 240 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 241 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
242 acid;
- 243 (s) Pethidine (meperidine);
- 244 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 245 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 246 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

- 247 (w) Phenazocine;
248 (x) Piminodine;
249 (y) Racemethorphan;
250 (z) Racemorphan;
251 (aa) Remifentanil;
252 (bb) Sufentanil;
253 (cc) Tapentadol;
254 (3) Any material, compound, mixture, or preparation which contains any quantity of the
255 following substances having a stimulant effect on the central nervous system:
256 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
257 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
258 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
259 (d) Phenmetrazine and its salts;
260 (e) Methylphenidate;
261 (4) Any material, compound, mixture, or preparation which contains any quantity of the
262 following substances having a depressant effect on the central nervous system, including its salts,
263 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
264 is possible within the specific chemical designation:
265 (a) Amobarbital;
266 (b) Glutethimide;
267 (c) Pentobarbital;
268 (d) Phencyclidine;
269 (e) Secobarbital;
270 (5) Any material or compound which contains any quantity of nabilone;
271 (6) Any material, compound, mixture, or preparation which contains any quantity of the
272 following substances:
273 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
274 (b) Immediate precursors to phencyclidine (PCP):
275 a. 1-phenylcyclohexylamine;
276 b. 1-piperidinocyclohexanecarbonitrile (PCC);
277 (7) Any material, compound, mixture, or preparation which contains any quantity of the
278 following alkyl nitrites:
279 (a) Amyl nitrite;
280 (b) Butyl nitrite.
281 5. The department of health and senior services shall place a substance in Schedule III
282 if it finds that:

- 283 (1) The substance has a potential for abuse less than the substances listed in Schedules
284 I and II;
- 285 (2) The substance has currently accepted medical use in treatment in the United States;
286 and
- 287 (3) Abuse of the substance may lead to moderate or low physical dependence or high
288 psychological dependence.
- 289 6. The controlled substances listed in this subsection are included in Schedule III:
- 290 (1) Any material, compound, mixture, or preparation which contains any quantity of the
291 following substances having a potential for abuse associated with a stimulant effect on the
292 central nervous system:
- 293 (a) Benzphetamine;
294 (b) Chlorphentermine;
295 (c) Clortermine;
296 (d) Phendimetrazine;
- 297 (2) Any material, compound, mixture or preparation which contains any quantity or salt
298 of the following substances or salts having a depressant effect on the central nervous system:
- 299 (a) Any material, compound, mixture or preparation which contains any quantity or salt
300 of the following substances combined with one or more active medicinal ingredients:
- 301 a. Amobarbital;
302 b. Secobarbital;
303 c. Pentobarbital;
- 304 (b) Any suppository dosage form containing any quantity or salt of the following:
- 305 a. Amobarbital;
306 b. Secobarbital;
307 c. Pentobarbital;
- 308 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
309 salt;
- 310 (d) Chlorhexadol;
311 (e) Embutramide;
- 312 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
313 a drug product for which an application has been approved under Section 505 of the federal
314 Food, Drug, and Cosmetic Act;
- 315 (g) Ketamine, its salts, isomers, and salts of isomers;
316 (h) Lysergic acid;
317 (I) Lysergic acid amide;
318 (j) Methyprylon;

- 319 (k) Sulfondiethylmethane;
- 320 (l) Sulfonethylmethane;
- 321 (m) Sulfonmethane;
- 322 (n) Tiletamine and zolazepam or any salt thereof;
- 323 (3) Nalorphine;
- 324 (4) Any material, compound, mixture, or preparation containing limited quantities of any
- 325 of the following narcotic drugs or their salts:
- 326 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 327 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
- 328 of opium;
- 329 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 330 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
- 331 therapeutic amounts;
- 332 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 333 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
- 334 isoquinoline alkaloid of opium;
- 335 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 336 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
- 337 ingredients in recognized therapeutic amounts;
- 338 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
- 339 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
- 340 recognized therapeutic amounts;
- 341 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
- 342 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
- 343 ingredients in recognized therapeutic amounts;
- 344 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
- 345 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
- 346 active nonnarcotic ingredients in recognized therapeutic amounts;
- 347 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
- 348 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
- 349 amounts;
- 350 (5) Any material, compound, mixture, or preparation containing any of the following
- 351 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;
- 352 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
- 353 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
- 354 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is

355 expressly intended for administration through implants to cattle or other nonhuman species and
 356 which has been approved by the Secretary of Health and Human Services for that administration.
 357 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
 358 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
 359 meaning of this paragraph. Unless specifically excepted or unless listed in another schedule, any
 360 material, compound, mixture or preparation containing any quantity of the following substances,
 361 including its salts, esters and ethers:

- 362 (a) $3\beta,17$ -dihydroxy- 5α -androstane;
 363 (b) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;
 364 (c) 5α -androstan- $3,17$ -dione;
 365 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);
 366 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);
 367 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
 368 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
 369 (h) 1-androstenedione ($[5\alpha]$ -androst-1-en- $3,17$ -dione);
 370 (I) 4-androstenedione (androst-4-en- $3,17$ -dione);
 371 (j) 5-androstenedione (androst-5-en- $3,17$ -dione);
 372 (k) Bolasterone ($7\alpha, 17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
 373 (l) Boldenone (17β -hydroxyandrost-1,4,-diene-3-one);
 374 (m) Boldione;
 375 (n) Calusterone ($7\beta, 17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
 376 (o) Clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);
 377 (p) D e h y d r o c h l o r o m e t h y l t e s t o s t e r o n e
 378 (4-chloro- 17β -hydroxy- 17α -methyl-androst-1,4-dien-3-one);
 379 (q) Desoxymethyltestosterone;
 380 (r) $\Delta 1$ -dihydrotestosterone (a.k.a. '1-testosterone')(17β -hydroxy- 5α -androst-1-en-3-one);
 381 (s) 4-dihydrotestosterone (17β -hydroxy-androstan-3-one);
 382 (t) Drostanolone (17β -hydroxy- 2α -methyl- 5α -androstan-3-one);
 383 (u) Ethylestrenol (17α -ethyl- 17β -hydroxyestr-4-ene);
 384 (v) Fluoxymesterone (9-fluoro- 17α -methyl- $11\beta,17\beta$ -dihydroxyandrost-4-en-3-one);
 385 (w) Formebolone (2-formyl- 17α -methyl- $11\alpha,17\beta$ -dihydroxyandrost-1,4-dien-3-one);
 386 (x) Furazabol (17α -methyl- 17β -hydroxyandrostano[2,3-c]-furazan);
 387 (y) 13β -ethyl- 17β -hydroxygon-4-en-3-one;
 388 (z) 4-hydroxytestosterone (4, 17β -dihydroxy-androst-4-en-3-one);
 389 (aa) 4-hydroxy-19-nortestosterone (4, 17β -dihydroxy-estr-4-en-3-one);
 390 (bb) Mestanolone (17α -methyl- 17β -hydroxy- 5α -androstan-3-one);

- 391 (cc) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
- 392 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
- 393 (ee) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
- 394 (ff) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
- 395 (gg) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane);
- 396 (hh) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane);
- 397 (ii) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
- 398 (j j) 1 7 α - m e t h y l - 4 - h y d r o x y n a n d r o l o n e
- 399 (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-one);
- 400 (kk) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
- 401 (ll) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
- 402 (mm) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
- 403 (nn) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
- 404 (o o) 1 7 α - m e t h y l - Δ 1 - d i h y d r o t e s t o s t e r o n e
- 405 (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
- 406 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
- 407 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
- 408 (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
- 409 (ss) 19-nor-4,9(10)-androstadienedione;
- 410 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
- 411 (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
- 412 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 413 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 414 (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
- 415 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
- 416 (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
- 417 (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
- 418 (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
- 419 (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
- 420 (d d d) O x y m e t h a l o n e
- 421 (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstan-3-one);
- 422 (eee) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
- 423 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
- 424 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
- 425 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
- 426 (iii) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);

427 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);

428 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this
429 subdivision, except an anabolic steroid which is expressly intended for administration through
430 implants to cattle or other nonhuman species and which has been approved by the Secretary of
431 Health and Human Services for that administration;

432 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
433 United States Food and Drug Administration approved drug product;

434 (8) The department of health and senior services may except by rule any compound,
435 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
436 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
437 195.320 if the compound, mixture, or preparation contains one or more active medicinal
438 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
439 admixtures are included therein in combinations, quantity, proportion, or concentration that
440 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
441 the central nervous system.

442 7. The department of health and senior services shall place a substance in Schedule IV
443 if it finds that:

444 (1) The substance has a low potential for abuse relative to substances in Schedule III;

445 (2) The substance has currently accepted medical use in treatment in the United States;

446 and

447 (3) Abuse of the substance may lead to limited physical dependence or psychological
448 dependence relative to the substances in Schedule III.

449 8. The controlled substances listed in this subsection are included in Schedule IV:

450 (1) Any material, compound, mixture, or preparation containing any of the following
451 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
452 as set forth below:

453 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
454 of atropine sulfate per dosage unit;

455 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
456 propionoxybutane);

457 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
458 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
459 upon the compound, mixture or preparation valuable medicinal qualities other than those
460 possessed by the narcotic drug alone:

461 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
462 one hundred grams;

463 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
464 or per one hundred grams;

465 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
466 or per one hundred grams;

467 (2) Any material, compound, mixture or preparation containing any quantity of the
468 following substances, including their salts, isomers, and salts of isomers whenever the existence
469 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 470 (a) Alprazolam;
- 471 (b) Barbital;
- 472 (c) Bromazepam;
- 473 (d) Camazepam;
- 474 (e) Chloral betaine;
- 475 (f) Chloral hydrate;
- 476 (g) Chlordiazepoxide;
- 477 (h) Clobazam;
- 478 (i) Clonazepam;
- 479 (j) Clorazepate;
- 480 (k) Clotiazepam;
- 481 (l) Cloxazolam;
- 482 (m) Delorazepam;
- 483 (n) Diazepam;
- 484 (o) Dichloralphenazone;
- 485 (p) Estazolam;
- 486 (q) Ethchlorvynol;
- 487 (r) Ethinamate;
- 488 (s) Ethyl loflazepate;
- 489 (t) Fludiazepam;
- 490 (u) Flunitrazepam;
- 491 (v) Flurazepam;
- 492 (w) Fospropofol;
- 493 (x) Halazepam;
- 494 (y) Haloxazolam;
- 495 (z) Ketazolam;
- 496 (aa) Loprazolam;
- 497 (bb) Lorazepam;
- 498 (cc) Lormetazepam;

- 499 (dd) Mebutamate;
500 (ee) Medazepam;
501 (ff) Meprobamate;
502 (gg) Methohexital;
503 (hh) Methylphenobarbital (mephobarbital);
504 (ii) Midazolam;
505 (jj) Nimetazepam;
506 (kk) Nitrazepam;
507 (ll) Nordiazepam;
508 (mm) Oxazepam;
509 (nn) Oxazolam;
510 (oo) Paraldehyde;
511 (pp) Petrichloral;
512 (qq) Phenobarbital;
513 (rr) Pinazepam;
514 (ss) Prazepam;
515 (tt) Quazepam;
516 (uu) Temazepam;
517 (vv) Tetrazepam;
518 (ww) Triazolam;
519 (xx) Zaleplon;
520 (yy) Zolpidem;
521 (zz) Zopiclone;
522 (3) Any material, compound, mixture, or preparation which contains any quantity of the
523 following substance including its salts, isomers and salts of isomers whenever the existence of
524 such salts, isomers and salts of isomers is possible: fenfluramine;
525 (4) Any material, compound, mixture or preparation containing any quantity of the
526 following substances having a stimulant effect on the central nervous system, including their
527 salts, isomers and salts of isomers:
528 (a) Cathine ((+)-norpseudoephedrine);
529 (b) Diethylpropion;
530 (c) Fencamfamin;
531 (d) Fenproporex;
532 (e) Mazindol;
533 (f) Mefenorex;
534 (g) Modafinil;

- 535 (h) Pemoline, including organometallic complexes and chelates thereof;
536 (I) Phentermine;
537 (j) Pipradrol;
538 (k) Sibutramine;
539 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
540 (5) Any material, compound, mixture or preparation containing any quantity of the
541 following substance, including its salts:
542 (a) butorphanol;
543 (b) pentazocine;
544 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
545 is the only active medicinal ingredient;
546 (7) The department of health and senior services may except by rule any compound,
547 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
548 subsection from the application of all or any part of sections 195.010 to 195.320 if the
549 compound, mixture, or preparation contains one or more active medicinal ingredients not having
550 a depressant effect on the central nervous system, and if the admixtures are included therein in
551 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
552 substances which have a depressant effect on the central nervous system.
- 553 9. The department of health and senior services shall place a substance in Schedule V
554 if it finds that:
555 (1) The substance has low potential for abuse relative to the controlled substances listed
556 in Schedule IV;
557 (2) The substance has currently accepted medical use in treatment in the United States;
558 and
559 (3) The substance has limited physical dependence or psychological dependence liability
560 relative to the controlled substances listed in Schedule IV.
- 561 10. The controlled substances listed in this subsection are included in Schedule V:
562 (1) Any compound, mixture or preparation containing any of the following narcotic
563 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
564 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
565 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
566 qualities other than those possessed by the narcotic drug alone:
567 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
568 twenty-five micrograms of atropine sulfate per dosage unit;
569 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
570 one hundred grams;

571 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
572 micrograms of atropine sulfate per dosage unit;

573 (2) Any material, compound, mixture or preparation which contains any quantity of the
574 following substance having a stimulant effect on the central nervous system including its salts,
575 isomers and salts of isomers: pyrovalerone;

576 (3) Any compound, mixture, or preparation containing any detectable quantity of
577 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
578 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
579 isomers, or salts of optical isomers;

580 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
581 material, compound, mixture, or preparation which contains any quantity of the following
582 substances having a depressant effect on the central nervous system, including its salts:

583 (a) Lacosamide;

584 (b) Pregabalin.

585 11. If any compound, mixture, or preparation as specified in subdivision (3) of
586 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
587 prescription:

588 (1) All packages of any compound, mixture, or preparation containing any detectable
589 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
590 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
591 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
592 registered pharmacy technician; and

593 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
594 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
595 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
596 shall be at least eighteen years of age; and

597 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
598 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,
599 or preparation to furnish suitable photo identification that is issued by a state or the federal
600 government or a document that, with respect to identification, is considered acceptable and
601 showing the date of birth of the person;

602 (4) The seller shall deliver the product directly into the custody of the purchaser.

603 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
604 implement and maintain an electronic log of each transaction. Such log shall include the
605 following information:

606 (1) The name, address, and signature of the purchaser;

- 607 (2) The amount of the compound, mixture, or preparation purchased;
608 (3) The date and time of each purchase; and
609 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
610 technician who dispensed the compound, mixture, or preparation to the purchaser.
- 611 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
612 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
613 transmission methods and frequency established by the department by regulation;
- 614 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
615 greater than those specified in this chapter.
- 616 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
617 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
618 where the public is not permitted.
- 619 16. Any person who knowingly or recklessly violates the provisions of subsections 11
620 to 15 of this section is guilty of a class A misdemeanor.
- 621 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
622 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
623 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
624 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
625 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.
- 626 18. The manufacturer of a drug product or another interested party may apply with the
627 department of health and senior services for an exemption from this section. The department of
628 health and senior services may grant an exemption by rule from this section if the department
629 finds the drug product is not used in the illegal manufacture of methamphetamine or other
630 controlled or dangerous substances. The department of health and senior services shall rely on
631 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
632 proposed product can be used to manufacture illicit controlled substances.
- 633 19. The department of health and senior services shall revise and republish the schedules
634 annually.
- 635 20. The department of health and senior services shall promulgate rules under chapter
636 536 regarding the security and storage of Schedule V controlled substances, as described in
637 subdivision (3) of subsection 10 of this section, for distributors as registered by the department
638 of health and senior services.
- 639 21. Logs of transactions required to be kept and maintained by this section and section
640 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
641 the person whose transactions are recorded in the logs.

195.202. 1. Except as authorized by sections 195.005 to 195.425, it is unlawful for any
2 person to possess or have under his control a controlled substance.

3 2. Any person who violates this section with respect to any controlled substance except
4 thirty-five grams or less of marijuana, Dexanabinol,
5 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10
6 a-tetrahydrobenzo[c]chromen-1-ol, Indole, or 1-butyl-3(1-naphthoyl)indole, Indole, or
7 1-pentyl-3(1-naphthoyl)indole, and Phenol, CP 47, 497 & homologues, or
8 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol), where side chain n=5, and
9 homologues where side chain n=4,6, or 7 is guilty of a class C felony.

10 3. Any person who violates this section with respect to not more than thirty-five grams
11 of marijuana, Dexanabinol,
12 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10
13 a-tetrahydrobenzo[c]chromen-1-ol, Indole, or 1-butyl-3(1-naphthoyl)indole, Indole, or
14 1-pentyl-3(1-naphthoyl)indole, and Phenol, CP 47, 497 & homologues, or
15 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol), where side chain n=5, and
16 homologues where side chain n=4,6, or 7 is guilty of a class A misdemeanor.

17 **4. In any case where the defendant claims that the substance possessed was**
18 **industrial hemp and not a controlled substance the burden of proof shall be on the**
19 **defendant to prove that the substance was industrial hemp and not a controlled substance.**

195.203. Notwithstanding any other provision of this chapter it shall be legal for
2 **any person who has not been convicted of any felony offense or any misdemeanor drug**
3 **related offense to grow and cultivate industrial hemp as defined in section 195.010.**